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This manuscript reviews the use of serial intravascular ultrasound (IVUS) examination of coronary atherosclerosis in recent observational
studies and randomized trials that revealed the effects of cholesterol-lowering and lipid-modifying therapies and offered novel insight into
plaque progression and regression. We discuss the value of plaque progression–regression as complementary imaging endpoint and poten-
tial surrogate marker of cardiovascular event risk. In addition, the progress in serial assessment of coronary plaque composition and plaque
vulnerability by radiofrequency-based analyses is reviewed. Finally, we report on the evaluation of true vessel remodelling in recent serial
IVUS trials and discuss the future perspective of serial invasive imaging of coronary atherosclerosis.
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Introduction
Coronary heart disease remains the leading cause of morbidity and
mortality worldwide. Established preventive pharmacological thera-
pies reduce cardiovascular event rates by only 30–40%. Given the
significant residual cardiovascular risk, there is need to develop
novel therapies to achieve even greater risk reduction.1 –5
However, such novel anti-atherosclerotic therapies must be care-
fully evaluated, with ultimate proof of benefit in clinical endpoint
studies. Increasingly, complementary imaging endpoint trials are
used in comprehensive drug development programmes.
Intravascular ultrasound (IVUS) provides real-time, high-
resolution, tomographic images of the lumen, and the atherosclero-
tic changes in the coronary vessel wall.4 –7 The invasive nature of this
imaging technique requires selective cannulation of the vessel by an
IVUS imaging catheter that incorporates within its,1 mm diameter
a miniaturized transducer that emits and receives high-frequency,
20–45 MHz, ultrasound depending on the system and type of cath-
eter. Detection of the contours of the leading edge of the lumen and
the media–adventitia interface permit direct measurements of
lumen and total vessel cross-sectional area and, therefore, calcu-
lation of absolute and percent plaque and media (or atheroma)
area.6,7 In addition, morphology, severity, and composition of coron-
ary atherosclerotic plaques can be determined. By using motorized
pullback devices, volumetric data can be obtained which are particu-
larly suitable when performing serial IVUS studies.4 –11
Recent trials have used serial IVUS imaging to investigate the
effect of anti-atherosclerotic drugs on coronary plaque geometry
and/or plaque composition (Table 1).12– 30 IVUS is indeed a par-
ticularly suitable technique for the serial assessment of coronary
atherosclerosis, given its relatively high image resolution, accurate
measurements, high measurement reproducibility, and ability to
early detect mild, angiographically silent atherosclerotic disease
that can be a precursor of future coronary events.4 –11 As a
result, increasing attention has been focused on the appropriate
role of serial IVUS imaging to study complementary surrogate end-
points during the development of novel pharmacological therapies
(Figure 1).3– 5,10,11 This review updates our current knowledge as
obtained from both observational serial IVUS studies and random-
ized IVUS trials of pharmacological interventions.
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Table 1 Summary of pharmacological intervention trials with serial volumetric intravascular ultrasound endpoints
Study Year Design Follow-up Patientsa Treatment Serial IVUS results
GAIN12 2001 Randomized open-label
multicentre
12 months 99 Atorvastatin vs. Usual care D Atheroma volume (%): +2.5+25 vs. +11.8+31, P ¼ 0.14 D
Hyperechogenicity index (%) +42.2+98 vs. +10.1+69, P ¼ 0.02
Nissen et al.13 2003 Randomized placebo-controlled
multicentre
5 weeks 47 r-ApoA-I Milano (ETC216) vs. Placebo D Atheroma volume (%): 21.06+3.17, P ¼ 0.02 vs. baseline
+0.14+3.09, P ¼ 0.97 vs. baseline
Jensen et al.14 2004 Non-placebo-controlled single
centre
15 months 40 Simvastatin D Atheroma volume (%): +6.3 (95% CI 2.4–10.1), P ¼ 0.002 vs. baseline
REVERSAL16 2004 Randomized multicentre 18 months 502 Atorvastatine 80 mg vs. Pravastatine
40 mg
D Atheroma volume (%): 20.4 (95% CI 22.4 to 1.5) vs. +2.7 (95% CI
0.2–4.7), P ¼ 0.02
ESTABLISH15 2004 Open-label randomized single
centre
6 months 48 Atorvastatin vs. Usual care D Atheroma volume (%): –13.1+12.8 vs. +8.7+14.9, P, 0.0001
A-PLUS17 2004 Randomized placebo-controlled
multicentre
24 months 755 Avasimibe vs. Placebo D Atheroma volume (%): +1.9+14.6 vs. 20.1+12.7, P ¼ ns
CAMELOT18 2004 Randomized placebo-controlled
multicentre
24 months 274 Amlodipine 10 mg vs. Enalapril 20 mg
vs. Placebo
D Atheroma volume (%): +0.5+3.9, P ¼ 0.31 vs. baseline +0.8+3.7,
P ¼ 0.08 vs. baseline +1.3+4.4, P, 0.001 vs. baseline
Yokoyama et al.19 2005 Randomized single centre 6 months 59 Atorvastatin 10 mg vs. Usual care D Atheroma volume (%): 23.2, P ¼ 0.024 vs. baseline 22.9, P ¼ 0.194 vs.
baseline (+IVUS-backscatter endpoints)
Kawasaki et al.20 2005 Open-label randomized single
centre
6 months 55 Atorvastatin 20 mg vs. Pravastatin
20 mg vs. Usual care
D Atheroma volume (%): +2, P ¼ ns vs. baseline +1, P ¼ ns vs. baseline 0,
P ¼ ns vs. baseline (+IVUS-backscatter endpoints)
ASTEROID21 2006 Open-label blinded endpoints
trial multicentre
24 months 349 Rosuvastatin 40 mg D Atheroma volume (%): 20.98+3.15, P, 0.001 vs. baseline
ACTIVATE22 2006 Randomized placebo-controlled
multicentre
18 months 408 Pactimibe vs. Placebo D Atheroma Volume (%): +0.59+0.25 vs. +0.69+0.25, P ¼ 0.77
ILLUSTRATE23 2007 Randomized placebo-controlled
multicentre
24 months 910 Atorvastatin monotherapy vs.
Atorvastatin + Torcetrapib
D Atheroma volume (%): +0.19+2.83 vs. +0.12+2.99, P ¼ 0.72
ERASE24 2007 Randomized placebo-controlled
multicentre
6 weeks 136 Reconstituted HDL (CSL-111) infusion
vs. Placebo (saline)
D Atheroma volume (%): 23.41 (IQR 26.55 to 1.88) vs. 21.62 (IQR
25.95 to 1.94), P ¼ 0.48 (+Plaque characterization index endpoints)
STRADIVARIUS27 2008 Randomized placebo-controlled
multicentre
18 months 676 Rimonabant vs. Placebo D Atheroma volume (%): +0.25 (95% CI 20.04 to 0.54) vs. +0.51 (95%
CI 0.22–0.80), P ¼ 0.22
PERISCOPE28 2008 Randomized multicentre 18 months 360 Glimepiride vs. Pioglitazone D Atheroma volume (%): +0.73 (95% CI 0.33–1.12) vs. 20.16 (95% CI
20.57–0.25), P ¼ 0.002
IBIS-229 2008 Randomized placebo-controlled
multicentre
12 months 239 Darapladib vs. Placebo D Atheroma volume (mm3): 25.0+28.0 vs. 24.9+32.7, P ¼ 0.95 D
Necrotic core volume (mm
3
): 20.5+13.9 vs. +4.5+17.9, P ¼ 0.012
(+Palpography endpoints)
ENCORE-II30 2009 Randomized placebo-controlled
single centre
24 months 193 Nifedipine vs. Placebo D Atheroma volume (%) +5.0 (95% CI 21.3 to 11.2) vs. +3.2 (95% CI
21.9 to 8.2), P ¼ 0.66 (+Endothelial function test endpoints)
aWith IVUS follow-up data; D, changes.
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LDL-cholesterol and IVUS plaque
progression
A relation between low-density lipoprotein (LDL) cholesterol
levels in vivo and the postmortem extent of coronary atherosclero-
sis was established by histopathological studies that were—by
nature—studies at a single point in time.31 Angiographic studies
of progression-regression of coronary atherosclerosis were
limited by the fact (i) that angiography showed the opacified silhou-
ette of the lumen only and (ii) that the variability of vascular remo-
delling prevented any reliable prediction of the dimensions of
plaques that form the basis of lumen narrowing. Using coronary
calcium scoring as an indirect measures of atherosclerotic
burden, serial electron beam tomography examinations showed
in 2002 that lipid-lowering therapy significantly decreased the pro-
gression of coronary calcification.32
Nevertheless, the relation between LDL-cholesterol levels and
the progressive enlargement of coronary plaques was not demon-
strated until 2003.33,34 In that observational study with IVUS cross-
sectional area measurements at baseline and 18+9 months of
follow-up, 60 patients treated by usual care including statins
showed a direct linear relation between LDL-cholesterol levels
and changes of plaque area in the left main stem. Despite some
methodological limitations, this study suggested that an
LDL-cholesterol value of 75 mg/dL could be the threshold below
which—for the entire patient population assessed—no increase
of atherosclerotic plaque dimensions may occur (Figure 2).33,34
Modification of lipid profile by
statins and IVUS plaque
progression
Subsequently, two large-scale pharmacological intervention trials
with serial volumetric IVUS were published, studying the effect
of statin therapy on coronary plaque progression–regression
(Figure 2).16,21 The Reversal of Atherosclerosis with Aggressive Lipid
Lowering (REVERSAL) trial tested in a prospective, randomized
manner the effect of 18 months of intensive vs. moderate
lipid-lowering therapy on coronary plaque progression.16 The
REVERSAL trial demonstrated that atorvastatin (80 mg) treatment
to a mean LDL-cholesterol level of 78 mg/dL stopped progression
of plaque volume.16 Our serial cross-sectional IVUS data and the
volumetric IVUS data of the REVERSAL trial are in good agreement
with clinical trials that found an additional effect of intensive
cholesterol-lowering therapy in high-risk patients.35,36 Several
smaller pharmacological intervention studies confirmed the
impact of LDL-cholesterol lowering with statins on plaque pro-
gression as assessed with serial IVUS.12,14,15
In 2006, the Study to Evaluate the Effect of Rosuvastatin on Intravas-
cular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID)
demonstrated for the first time that very high-intensity statin
therapy with 40 mg rosuvastatin to a mean LDL-cholesterol level
of 60.8 mg/dL resulted in significant regression of atherosclerotic
plaque volume as assessed with serial IVUS.21 However, the
ASTEROID trial had no control group.21 Therefore, the ongoing
Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosu-
vastatin vs. Atorvastatin (SATURN) compares the two statins in a
randomized double blind multicentre design.37
Non-statin modification of lipid
profile and IVUS plaque
progression
Besides statins, other novel cholesterol modifying agents have been
evaluated in serial IVUS studies.17,22,23 Cholesterol esterification by
the enzyme acyl-coenzyme-A cholesterol acyltransferase (ACAT)
plays an important role in atherosclerotic plaque formation; inhi-
bition of ACAT may therefore influence atherosclerosis pro-
gression.22 However, two serial IVUS studies showed no
significant difference in plaque progression between patients
treated with ACAT inhibitors vs. placebo.17,22 This is an example
of how negative serial IVUS studies avoided further large-scale
clinical endpoint trials in drug-development programmes.
However, additional outcome-driven trials may be necessary to
Figure 1 Serial IVUS assessment of coronary atherosclerosis progression.
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clearly show effects on morbidity and mortality. Our above-
mentioned observational study suggested a significant negative
linear relation between high-density lipoprotein (HDL) cholesterol
and atherosclerotic plaque progression; low HDL-cholesterol was
on average associated with greater plaque progression.33 A small,
randomized serial IVUS trial suggested that 5-week infusions of a
HDL-mimic drug (Apo-A1 Milano) induced significant regression
of plaque volume in patients with acute coronary syndrome.13
A larger randomized, multicentre, serial IVUS trial found no signifi-
cant regression of coronary atherosclerosis in response to
infusions of another HDL-mimetic drug.24 Other novel cardiovas-
cular drugs, such as the cholesteryl-ester-transfer-protein-inhibitor
torcetrapib achieved a substantial increase in HDL-cholesterol
levels, but no significant decrease in coronary plaque progression
as determined with serial IVUS.23 The lack of efficacy of this
drug may be related either to its mechanism of action or to specific
adverse effects, such as an increase in arterial hypertension.23
Nevertheless, therapeutic increase in HDL-cholesterol remains a
valid target of preventive medicine and further research on how
to achieve this goal is certainly warranted.38
Metabolic regulation and IVUS
plaque progression
Using serial IVUS, the Progression of Coronary Atherosclerosis in Patients
With Type 2 Diabetes (PERISCOPE) trial compared pioglitazone vs.
glimepiride during 18 months of treatment with regard to their
effect on plaque progression–regression.28 Patients on the insulin-
sensitizer pioglitazone showed no further plaque progression
while glimepiride-treated patients had unequivocal progression of
atherosclerosis (change in percent plaque volume; P ¼ 0.002).28
Another trial that investigated the effect of improving metabolic
regulation on coronary plaque progression was the Strategy to
Reduce Atherosclerosis Development Involving Administration of Rimona-
bant—The Intravascular Ultrasound Study (STRADIVARIUS).27 This
randomized, double-blinded, placebo-controlled trial investigated
the effect of the selective cannabinoid type-1 receptor antagonist
rimonabant (that has positive metabolic effects in obese patients
with metabolic syndrome) on coronary aterial progression–
regression in patients with abdominal obesity, metabolic syndrome,
and coronary atherosclerosis.27 After 18 months rimonabant failed
to show an effect on changes in percent plaque volume (P ¼ 0.22),
the primary endpoint, but showed a favourable effect on changes in
total atheroma volume (P ¼ 0.03), a secondary endpoint.27
However, to date the drug has been withdrawn because of con-
cerns over the risk of psychiatric disorders.
Antihypertensive treatment and
IVUS plaque progression
Serial IVUS studies have also been used to investigate potential
effects of antihypertensive drugs on coronary plaque pro-
gression–regression. In the Norvasc for Regression of Manifest Ather-
osclerotic Lesions by Intravascular Sonographic Evaluation
(NORMALISE) substudy of the Comparison of Amlodipine vs. Enala-
pril to Limit Occurrences of Thrombosis (CAMELOT) trial, 274 patients
were examined with serial IVUS during a follow-up interval of 20
months.18 Compared with baseline, IVUS showed progression in
the placebo group (P, 0.001), a trend towards progression in
the enalapril group (P ¼ 0.08), and no progression in the amlodi-
pine group (P ¼ 0.31).18 In a pooled analysis of several IVUS
trials (n ¼ 1115, follow-up 18–24 months) , Sipahi et al26 demon-
strated that beta-blocker treatment can slow progression of cor-
onary atherosclerosis (change in atheroma volume: 22.4+
0.5 mm3/year in treated patients vs. 20.4+0.8 mm
3
/year in
untreated patients; P ¼ 0.034). A randomized study on the Effect
Figure 2 Low-density lipoprotein (LDL) cholesterol vs. coronary plaque progression–regression as assessed with serial intravascular ultra-
sound (image reproduced with permission from5). Demonstration of the positive significant relation between coronary plaque cross-sectional
area progression and LDL-cholesterol levels in a first observational study (left graph, modified from33). Relation between LDL-cholesterol and
mean change in coronary atheroma volume by data derived from several large multicentre trials (right graph, modified from21). Of note, as IVUS
is unable to distinguish between plaque (atheroma) and media, plaque measurements actually represent plaque + media.
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of Nifedipine on Coronary Endothelial Function and Plaque Formation in
Patients with Coronary Artery Disease (ENCORE II) demonstrated
that calcium channel blockade with nifedipine-improved coronary
endothelial function on top of statin treatment, but did not show
an effect of nifedipine on plaque volume.30
Potential of plaque progression by
serial IVUS as surrogate marker of
cardiovascular risk
The assessment of morbidity and mortality as primary endpoints in
conventional large-scale clinical trials of established and novel
agents is associated with a substantial financial burden.2– 5 Comp-
lementary surrogate imaging endpoint studies may allow smaller
study sample size and shorter study duration to expedite the
process of drug development and testing to evaluate the potential
benefits of novel anti-atherosclerotic drugs much before necessary
clinical endpoint data are available—an approach that may reduce
cost and inefficient (or even harmful) treatment. However, an
important pre-requisite of complementary surrogate endpoint
studies is evidence that the surrogate endpoint (i.e. imaging)
reflects clinical outcome: in the case of coronary atherosclerosis,
this is cardiovascular events. Quantitative coronary angiographic
studies have shown that progressive obstruction of the coronary
lumen (i.e. indirect evidence of plaque progression) is associated
with an increased risk of adverse cardiovascular events.39– 41
Therefore, it may be extrapolated that plaque progression, as
quantified with serial IVUS (i.e. direct evidence of plaque pro-
gression) should show (a similar or even) stronger association
with cardiovascular event risk. In the absence of a clear proof by
a randomized study that directly address this question, there is evi-
dence from several IVUS studies that supports this thesis.5
First, in a non-serial IVUS study by Ricciardi et al.42 angiographi-
cally silent atherosclerosis of the left main coronary artery as
detected by IVUS was an independent predictor of future
adverse cardiac events. In 102 studied patients, major adverse
cardiac events occurred in 38% during a follow-up of 29 months;
by multivariate analysis only IVUS assessed minimum lumen area
and diabetes mellitus were independent significant predictors of
these events.42
Second, data obtained by our group suggested that plaque pro-
gression as measured by IVUS was associated with a significantly
increased risk of clinical events as predicted by established risk
scores.43 During follow-up of that small observational study,
actual adverse cardiovascular events occurred predominantly in
patients with the greatest rate of plaque progression (P, 0.001,
Figure 3).43
Third, large prospective trials have also provided evidence that
supports this hypothesis. In pharmacological intervention trials
with clinical endpoints, IVUS was used in subgroups as a secondary
endpoint to assess changes in atherosclerotic plaque dimen-
sions.18,25 A trial evaluating intensive antihypertensive therapy
with amlodipine reported concordant reduction in adverse clinical
cardiovascular events and reduced coronary plaque progression as
assessed with serial IVUS.18 Patients with coronary artery disease
and normal blood pressure (n ¼ 1991) were randomized to
receive either 10 mg amlodipine, 20 mg enalapril, or placebo.
The cardiovascular event-rate was significantly lower in
amlodipine-treated patients compared with placebo-treated
patients (16.6 vs. 23.1%, P ¼ 0.003), while it did not differ signifi-
cantly between enalapril-treated patients and placebo group
(20.3 vs. 23.1%, P ¼ 0.16).18 A subgroup of these patients (n ¼
274) had serial IVUS with a follow-up after 2 years. In parallel
with the clinical endpoints, there was no change in plaque
volume in the amlodipine group (P ¼ 0.31), while plaque volume
increased non-significantly in the enalapril group (P ¼ 0.08) and
significantly in the placebo group (P, 0.001).18
Finally, the REVERSAL study used the same treatment regimen
as the clinical Pravastatin or Atorvastatin Evaluation and Infection
Therapy (PROVE IT) trial, which reported a significantly greater
reduction in cardiovascular events in patients with acute coronary
syndromes after treatment with 80 mg/day atorvastatin for
2 years.16,36 REVERSAL and PROVE IT were distinct studies, but
when considered together their results provide inferential evi-
dence that atherosclerotic progression measured by IVUS may
be predictive of an increased risk of cardiovascular events.16,36
Serial IVUS assessment of plaque
composition
Both, progression of the size of the atherosclerotic plaque and its
unfavourable tissue composition contribute to the risk of cardio-
vascular events.39–41,44– 46 As outlined above, progression–
regression studies with serial IVUS reported a beneficial effect
of anti-atherosclerotic pharmacological therapies on the pro-
gression of atherosclerotic plaque size—a geometrical
measure.12 –16,18,21,26– 28 However, there appears to be a discor-
dance between the highly significant clinical benefit of certain
pharmacological interventions and their quite limited effect on
plaque size that perhaps could be explained by a stabilizing effect
on plaque composition.5,12,19,20,24
Schartl et al.13 used a straightforward computer-aided grey-scale
IVUS analysis method to detect changes of plaque echogenicity that
Figure 3 Serial IVUS assessed changes in coronary plaque
dimensions vs. actual adverse cardiovascular events in an obser-
vational study (modified from von Birgelen et al.43).
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may reflect plaque composition. Lipid-lowering to LDL-cholesterol
levels below 100 mg/dL with atorvastatin (compared with usual
care) led to a significantly larger increase in plaque hyperechogeni-
city which was thought to reflect an increase in fibrous tissue indicat-
ing plaque stabilization.13 Conventional grey-scale IVUS (Figure 4A)
permits accurate geometric quantification of lumen and plaque
dimensions, but it has significant limitations in the assessment of
plaque composition.4 – 7,47,48 Therefore, spectral analysis of IVUS
radiofrequency (RF) data has been developed (Figure 4B) that quan-
tifies coronary plaque components (e.g. the necrotic core) with a
high predictive accuracy as demonstrated in vitro and in vivo.47 –50
Non-serial RF-IVUS studies provided interesting insights in the path-
ology of coronary atherosclerosis and demonstrated the ability to
detect features of plaque vulnerability (e.g. necrotic core and thin-
caped fibro-atheromas) in patients with unstable clinical presen-
tation.51– 53 Given its relatively good measurement reproducibil-
ity,54,55 RF-IVUS seems to be a suitable image modality for the
serial assessment of plaque composition during pharmacological
interventions.19,20,29 Kawasaki et al.20 demonstrated plaque stabiliz-
ation (decrease in necrotic and increase in fibrous tissue) with statin
therapy in a serial RF-IVUS study. Recently, the first multicentre, ran-
domized, placebo-controlled pharmacological intervention trial Inte-
grated Biomarker And Imaging Study-2 (IBIS-2) used changes of
RF-IVUS-derived volumetric data as an endpoint to test the effect
of inhibition of the enzyme lipoprotein-associated phospholipase-A2
with darapladib on plaque geometry and composition.29 In addition,
serial palpography—an IVUS method that assesses the local mech-
anical properties of plaque tissue based on deformation caused by
the intraluminal pressure—was used to assess changes in local
plaque strain (high-strain regions at the lumen–plaque interface
had a high predictive value for the detection of vulnerable
plaques).29,56 There was no significant difference in changes in
plaque strain between groups, but the RF-IVUS data showed that
the necrotic core volume—a key determinant of plaque vulner-
ability—continued to increase among patients receiving placebo
while this was not the case in patients with darapladib treatment.29
Specific RF-IVUS plaque characteristics are related to known
risk factors of sudden cardiac death.57 Nevertheless, the relation
between serial changes of plaque composition as assessed with
RF-IVUS and clinical endpoints has still to be demonstrated.47,48,58
The natural history study Providing Regional Observations to Study Pre-
dictors of Events in the Coronary Tree (PROSPECT) found a relation
between some RF-IVUS plaque characteristics and subsequent
cardiac events, which may in the future potentially help to identify
high-risk patients before adverse cardiac events occur.58 Histo-
pathological studies demonstrate that vulnerable plaques are gen-
erally characterized by a necrotic core and a thin fibrous cap
(cap thickness ,65 mm).44 –46 RF-IVUS can visualize and
measure the necrotic core, but is unable to visualize such a thin
fibrous cap because of its image resolution of approximately
100 mm.47,48 Nevertheless, that thin fibrous cap is a defining
feature of plaques ‘prone to rupture’.44–46 Optical coherence tom-
ography (OCT, Figure 4C) provides images of intimal structures
including the accurate visualization of thin fibrous caps (resolution
approximately 10 mm).59– 61 For instance, serial OCT imaging
demonstrated a significant increase in fibrous cap thickness
during statin therapy.61 However, OCT is unable to reliably
detect a large and deep necrotic core, because its penetrance is
limited.11,60 Recently, Sawada et al.60 demonstrated a more effec-
tive detection of vulnerable plaques by combined use of the two
complementary imaging modalities: OCT plus IVUS.
Serial IVUS investigation of
coronary vessel remodelling
Arterial remodelling, as first described by Glagov et al.,62 describes
characteristic changes of arterial size during plaque progression–
regression. Expansive arterial remodelling is defined as an increase
in vessel size during progression and is associated with inflam-
mation, and unstable clinical presentation.63–66 Based on these
observations, expansive remodelling is recognized as a character-
istic of unstable-vulnerable lesions. These findings have generated
the hypothesis that plaque stabilizing, pharmacological intervention
may be associated with constrictive remodelling. Serial IVUS
observations confirmed a broad spectrum of remodelling
responses in mild-to-moderate atherosclerotic coronary lesions
by assessing changes of the total vessel size over time.67– 69
Reanalysis of serial IVUS data from trials that tested the effect of
anti-atherosclerotic drugs on plaque size (progression–regression)
Figure 4 Technical progress may lead to the development of imaging catheters which may integrate grey-scale IVUS (A), radiofrequency-
based IVUS (B), and optical coherence tomography (C, not the same plaque as in A or B).
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revealed interesting insights into the serial remodelling behaviour
during pharmacological intervention.70–74 Schoenhagen et al.72
observed negative remodelling of the coronary vessel wall during
plaque stabilizing therapy with statins that appeared to be related
to their anti-inflammatory effects (Figure 5). Schartl et al.70 showed
that the positive remodelling process is diminished in patients with
plaque progression despite intense lipid-lowering therapy. Based
on their serial IVUS findings, Tardif et al.71 concluded that regression
of atherosclerotic plaque is generally accompanied by negative remo-
delling without an increase in lumen dimensions (‘reverse vascular
remodelling’). Rodriguez-Granillo et al.74 reported arterial remodel-
ling data from an imaging substudy of the EUROPA study, which
demonstrated that the angiotensin-converting enzyme inhibitor peri-
ndopril reduced clinical events in patients with stable coronary artery
disease. Imaging sub-studies, found no effect on angiographic luminal
diameter or plaque burden assessed by IVUS.25 In contrast there was
more frequent constrictive remodelling during follow-up.74
These data demonstrate that, beside the reduction in plaque size
(regression), a shift of the remodelling pattern towards negative
remodelling may be considered as a sign of plaque stabiliz-
ation.70– 74However, the role of the remodelling state or behaviour
as an independent complementary surrogate endpoint in serial
IVUS trials has not yet been defined.75
Conclusion
As the global burden of cardiovascular disease increases, there is
need for complementary surrogate endpoints to maximize efficacy
in the evaluation of new anti-atherosclerotic therapies.4,5,76 Most
coronary events are associated with complex interaction
between both progression of plaque size and changes of atheroma
composition.39– 41,44– 46 As current non-invasive imaging tech-
niques still have significant limitations for the serial assessment of
coronary atherosclerosis, invasive imaging with IVUS remains for
the time being the gold standard.11,76 RF-based IVUS analysis
permits quantitative assessment of atherosclerotic plaque compo-
sition. As a consequence, serial RF-IVUS data are increasingly
incorporated in pharmacological intervention trials.19,20,29,47,48
The development of a single image catheter that permits simul-
taneous imaging with both IVUS (including RF-analysis) and OCT
during a single pullback is currently underway. In the future, such
technical advances will provide additional insights into the natural
history of coronary atherosclerosis and may allow further improve-
ment of complementary surrogate endpoints for trials that aim at
further reduction in cardiovascular morbidity and/or mortality.
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